Nevertheless, a recent study has demonstrated that the common MHC class I component β2-microglobulin can bind to the inhibitory receptor LILRB1 of macrophages, thereby protecting tumor cells from phagocytosis and promoting resistance to immunotherapy (73). This evidence concerns the gene LILRB1 and neoplasm.